Comparing the cost-effectiveness of immunotherapy strategies in BRAF wild-type advanced melanoma

Authors :: Alberto J. Montero
Christine G. Kohn
Qiushi Chen
Simon B. Zeichner
Christopher R. Flowers
Daniel A. Goldstein
Source :: Journal of Clinical Oncology. 34:6607-6607
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 6607Background: Patients (pts) diagnosed with unresectable stage III or IV melanoma have 5-year survival rates of 15-20%. Recent FDA approved treatment options include pembrolizumab (PEM), nivoluma...

Tools